Press Releases

All News
By Year:
2019
2018
2017
2016

Feb 14, 2019

DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease

Jan 22, 2019

DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders

Jan 9, 2019

DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange

Jan 3, 2019

DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease

Dec 7, 2018

DiaMedica Announces Pricing of Initial Public Offering and Nasdaq Listing

Nov 12, 2018

DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation

Nov 6, 2018

DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders

Sep 27, 2018

DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke

Sep 5, 2018

DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer

May 3, 2018

DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease

1
2
3
4
5
Next >>